It says it should have wrapped up this last May
clinicaltrials.gov/ct2/show...
Detailed Description:
This clinical trail was a multicenter, parallel, randomized, double-blind, placebo-controlled study led by Professor Liu Chunfeng from the Second Affiliated Hospital of Suzhou University which consisted of 15 sub-centers with a total of 180 subjects.
This clinical study is divided into two phases:
The first stage: double-blind period, 24 weeks. Three queues containing idebenone 180 mg/d,360 mg/d and placebo.
The second stage: open label extension period, 24 weeks. All enrolled participants continued to take idebenone 180 mg/d to study the long-term effects of idebenone.
Hot off the press. Randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease.
New Clinical Study regarding Mucuna Pruriens
Results of a Phase 1b trial of MODAG's oligomer modulator anle138b evaluating the safety tolerability in healthy volunteers
B1 Therapy question
